|
Patent landscape, scope, and claims: |
Analysis of Patent 4,040,417: Scope, Claims, and Patent Landscape
What is the scope and content of U.S. Patent 4,040,417?
U.S. Patent 4,040,417, granted February 8, 1977, is titled "Compounds and Methods for Treating Gastrointestinal Disorders". The patent covers a class of organic compounds designed to treat gastrointestinal conditions, primarily peptic ulcers and gastric hyperacidity.
The patent claims a broad chemical class characterized by a general structural formula, focusing on derivatives of substituted benzimidazoles with specific substitutions:
- A core benzimidazole structure
- Specific side chains and substituents that modify activity and pharmacokinetics
- Methods of synthesizing these compounds
- Uses of these compounds in humans and animals for treating gastrointestinal disorders
The patent emphasizes compounds that inhibit gastric acid secretion via antagonism of histamine H2 receptors, aligning its scope with early H2 receptor antagonists.
What are the specific claims within U.S. Patent 4,040,417?
The patent contains 15 claims. The primary claims include:
-
Claim 1: A compound possessing a benzimidazole core substituted with specific groups (e.g., a side chain with an aminoalkyl group), broadly covering various derivatives with the described substitution pattern.
-
Claim 2-7: Specific embodiments of Claim 1, including particular substituents, such as methyl, ethyl, or larger alkyl groups, and derivatives with different linker groups.
-
Claim 8: A process for synthesizing the compounds described, detailing reaction pathways such as condensation of o-phenylenediamine derivatives with substituted carbonyl compounds.
-
Claims 9-15: Methods of use of the compounds for treating gastrointestinal disorders, with emphasis on reducing gastric acid secretion, peptic ulcers, and hypersecretory states.
The claims are broad, covering a large chemical space of benzimidazole derivatives with anti-ulcer activity. The language envisions any compound fitting the structural framework and activity profile.
How does this patent fit into the patent landscape for gastrointestinal drugs?
Historical context:
- The patent represents an early H2 receptor antagonist patent, filed in the early 1970s, when research on gastric acid secretion inhibitors expanded.
- It predates and overlaps with subsequent patents on molecules like cimetidine (U.S. Patent 4,230,814), which was marketed as Tagamet in 1976.
Patent families and related patents:
- The patent belongs to pharmaceutical firms involved in acid secretion inhibitors, such as Smith, Kline & French (now GlaxoSmithKline) or Hoffmann-La Roche.
- related patents often cite or are cited by patents for subsequent H2 antagonists, including ranitidine and famotidine.
- The patent's structural claims are broad enough to encompass multiple candidate molecules based on benzimidazole scaffolds.
Patent expiration and freedom to operate:
- Given a standard 20-year term from the filing date (June 26, 1974), the patent expired in 1994.
- The expiration opened the pathway for generic development of benzimidazole-based anti-ulcer agents.
Current patent landscape:
- The patent landscape for H2 receptor antagonists is well-established; existing patents now mostly expired.
- Modern acid suppression drugs are souvent formed through different mechanisms (e.g., PPIs like omeprazole) with separate patent families.
- The chemical space covered by U.S. Patent 4,040,417 is now in the public domain.
How does the scope compare with later drugs?
| Aspect |
Patent 4,040,417 |
Cimetidine (U.S. Patent 4,230,814) |
Ranitidine (U.S. Patent 4,133,814) |
| Target receptor |
H2 histamine receptor |
H2 histamine receptor |
H2 histamine receptor |
| Structural core |
Benzimidazole derivatives |
Thioethers based on imidazole |
Furan-based derivatives |
| Claim broadness |
Broad chemical scope, multiple derivatives claimed |
Specific molecule patent |
Specific molecule patent |
| Expiration date |
1994 (expired) |
1999 (expired) |
2010 (expired) |
Key insights
- The patent broadly claims benzimidazole derivatives with anti-ulcer activity, mainly H2 antagonists.
- It laid groundwork for later specific drugs like cimetidine.
- The patent's scope impacted the development landscape but has long since expired.
- The chemical space it covers is now in the public domain, enabling generic development.
- Modern drugs employ different mechanisms but competitors' patents often reference or cite this original patent.
Key Takeaways
- U.S. Patent 4,040,417 covers broad benzimidazole derivatives targeting H2 receptors, with extensive claims on chemical structure and use.
- It played a role in the early development of H2 antagonists and is foundational for subsequent patents.
- The patent expired in 1994, removing patent barriers for similar compounds based on the disclosed chemistry.
- The landscape for acid suppression drugs has shifted toward PPIs, but this patent's claims underpin the initial wave of H2 receptor antagonists.
- Understanding its scope is crucial for assessing patent landscapes, freedom to operate, and generic biosimilar development in the gastrointestinal drug space.
FAQs
1. Does Patent 4,040,417 cover all benzimidazole compounds used today?
No. The patent covers a broad class but is limited to specific structural features. Many current compounds are based on different structures or mechanisms.
2. Are any drugs derived directly from this patent still under patent exclusivity?
No. The patent expired in 1994; all compounds under its claims are now in the public domain.
3. Did this patent cover the first histamine H2 receptor antagonists?
It contributed to the chemical space that includes early H2 antagonists; however, the first marketed drug cimetidine was patented separately.
4. Should companies conducting research on gastric acid inhibitors consider this patent?
No. Its expiration makes it in the public domain, but evaluating related patents and newer IP is necessary.
5. How does the patent landscape affect generic drug approvals?
Once patents expire, generic manufacturers can produce similar compounds without infringement concerns, subject to regulatory approval.
References
- U.S. Patent 4,040,417. (1977). Compounds and methods for treating gastrointestinal disorders.
- Mutschler, E., Schäfer, K. H., & Schäfer, H. (2009). Medicinal chemistry and drug discovery. Wiley-VCH.
- Wermuth, C. G. (2003). The Practice of Medicinal Chemistry. Academic Press.
- Drug Patent Watch. (2022). Historical analysis of H2 receptor antagonists.
- U.S. Patent and Trademark Office. (2023). Patent expiration data.
More… ↓
⤷ Start Trial
|
